{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:59:07Z","timestamp":1793228347853,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pharma Mar S.A"},{"name":"Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center San Antonio, San Antonio, TX, USA"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.lungcan.2020.10.003","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T04:53:58Z","timestamp":1602305638000},"page":"90-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment"],"prefix":"10.1016","volume":"150","author":[{"given":"Vivek","family":"Subbiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Angeles","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"L\u00f3pez-Vilari\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Kahatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Siguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Zeaiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Arrondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Wannesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Valdivia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Olmedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sarantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sant P.","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mosquera-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolo","family":"D\u2019 Arcangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1016\/j.lungcan.2020.10.003_bib0005","doi-asserted-by":"crossref","first-page":"vi99","DOI":"10.1093\/annonc\/mdt178","article-title":"Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Fruh","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.10.003_bib0010","article-title":"NCCN clinical practice guidelines in oncology","year":"2020","journal-title":"Small Cell Lung Cancer"},{"issue":"23","key":"10.1016\/j.lungcan.2020.10.003_bib0015","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.lungcan.2020.10.003_bib0020","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"C. investigators, Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.lungcan.2020.10.003_bib0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12094-012-0960-6","article-title":"Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis","volume":"15","author":"Korkmaz","year":"2013","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.10.003_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.lungcan.2015.04.012","article-title":"Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702","volume":"89","author":"Inoue","year":"2015","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2020.10.003_bib0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/COC.0b013e318286907b","article-title":"Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer","volume":"38","author":"Wakuda","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2020.10.003_bib0040","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/j.cllc.2015.04.006","article-title":"Outcomes of platinum-sensitive small-cell lung Cancer patients treated with Platinum\/Etoposide rechallenge: a multi-institutional retrospective analysis","volume":"16","author":"Genestreti","year":"2015","journal-title":"Clin. Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2020.10.003_bib0045","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1159\/000492780","article-title":"Rechallenge with first-line platinum chemotherapy for sensitive-relapsed small-cell lung Cancer","volume":"11","author":"Shiozawa","year":"2018","journal-title":"Case Rep. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.10.003_bib0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12032-018-1123-6","article-title":"Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer","volume":"35","author":"Naito","year":"2018","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2020.10.003_bib0055","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.21873\/invivo.11727","article-title":"Efficacy of second-line chemotherapy in patients with sensitive relapsed small-cell lung Cancer","volume":"33","author":"Wakuda","year":"2019","journal-title":"In Vivo"},{"issue":"10","key":"10.1016\/j.lungcan.2020.10.003_bib0060","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.1016\/j.jtho.2019.08.490","article-title":"OA15.02 carboplatin-etoposide versus topotecan as second-line treatment for sensitive relapsed small-cell lung Cancer: phase 3 trial","volume":"14","author":"Monnet","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2020.10.003_bib0065","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ccell.2014.10.019","article-title":"Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor","volume":"26","author":"Christensen","year":"2014","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.lungcan.2020.10.003_bib0070","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2020.10.003_bib0075","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1476-5381.2010.00945.x","article-title":"PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity","volume":"161","author":"Leal","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.lungcan.2020.10.003_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells","volume":"15","author":"Santamaria Nunez","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"22","key":"10.1016\/j.lungcan.2020.10.003_bib0085","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1158\/0008-5472.CAN-16-0568","article-title":"Lurbinectedin inactivates the ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus","volume":"76","author":"Harlow","year":"2016","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2020.10.003_bib0090","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2020.10.003_bib0095","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.10.003_bib0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2020.10.003_bib0105","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/0277-5379(87)90128-3","article-title":"Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy","volume":"23","author":"Postmus","year":"1987","journal-title":"Eur. J. Cancer Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2020.10.003_bib0110","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/0277-5379(87)90452-4","article-title":"Reinduction chemotherapy in small cell lung cancer","volume":"23","author":"Giaccone","year":"1987","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.10.003_bib0115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.lungcan.2019.03.028","article-title":"F. Multidisciplinary Thoracic Oncology Group Grenoble University Hospital, Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017","volume":"131","author":"Lattuca-Truc","year":"2019","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2020.10.003_bib0120","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.21037\/jtd.2016.09.28","article-title":"Relapsed small-cell lung cancer: platinum re-challenge or not","volume":"8","author":"Rossi","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2020.10.003_bib0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.lungcan.2020.03.024","article-title":"Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts","volume":"146","author":"Fruh","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.10.003_bib0130","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/TCRM.S183216","article-title":"Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan","volume":"15","author":"DiBonaventura","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.lungcan.2020.10.003_bib0135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.lungcan.2019.02.026","article-title":"Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study","volume":"130","author":"Steffens","year":"2019","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2020.10.003_bib0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219622","article-title":"Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: a systematic literature review (SLR)","volume":"14","author":"Povsic","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2020.10.003_bib0145","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion-variation\/hycamtin-h-c-123-ii-0034-epar-scientific-discussion-variation_en.pdf. (Accessed 22 June 2020)."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:45:16Z","timestamp":1759236316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220306401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":29,"alternative-id":["S0169500220306401"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.10.003","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}